Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brodalumab in Axial Spondyloarthritis (Phase 2, Randomized, Double-blind, Placebo-controlled, UK)
2014-003701-15Phase 2Terminated
- Sponsor
- Amgen
- Start
- Apr 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in axial spondyloarthritis (axSpA), ankylosing spondylitis (AS) and spondyloarthritis (SpA) comparing Brodalumab with Placebo (2 arms). Primary endpoint: ASAS 20 response at week 16. Started Apr 2015; status: terminated.
02
Drugs
brodalumab
03
Conditions
axial spondyloarthritis (axSpA)ankylosing spondylitis (AS)spondyloarthritis (SpA)
Beyond the preview
Go deeper on 2014-003701-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003701-15.